News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sedia Biosciences Receives $1.0 Million National Institutes of Health (NIH) Grant For New HIV Diagnostic Assay



2/12/2014 8:02:07 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PORTLAND, Ore.--(BUSINESS WIRE)--Sedia Biosciences Corporation of Portland, Oregon announced today that it has received a Notice of Award granting Phase II funding of its previous Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health. The Phase II funding is to continue development and commercialization for diagnostic use of Sedia’s HIV-1 Limiting Antigen (“LAg”)-Avidity EIA, a novel single well enzyme assay based on U.S. Centers for Disease Control and Prevention (“CDC”) licensed technology.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES